TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06130748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Hyrax
Description: these patents will be treated using Two mini-screws supported hybrid hyrax
Study: NCT05552209

Intervention type: DEVICE
Intervention: Elbow MID 500
Description: 15 patients will be included in this group and will used the medical device Elbow MID 500 during sport practice (at least 2 sport sessions per week), for 6 weeks.

Intervention type: OTHER
Intervention: Control group Elbow MID 500
Description: 15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device Elbow MID 500), for at least 2 sport sessions per week during 6 weeks.

Intervention type: DEVICE
Intervention: Elbow STRAP
Description: 15 patients will be included in this group and will used the medical device Elbow STRAP during sport practice (at least 2 sport sessions per week), for 6 weeks.

Intervention type: OTHER
Intervention: Control group Elbow STRAP
Description: 15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device Elbow STRAP), for at least 2 sport sessions per week during 6 weeks.
Study: NCT04951401

Intervention type: OTHER
Intervention: lipid profile
Description: lipid profile

Intervention type: OTHER
Intervention: ECG
Description: ECG
Study: NCT06127030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioral teacher training
Description: A brief behavioral teacher training program that combines individually-tailored stimulus control and contingency management techniques to treat children's behavioral difficulties in two (bi)weekly training sessions of two hours and a third session of one hour in which the training will be evaluated and maintenance training will be provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Practice as usual only (PAU)
Description: PAU may include any support or treatment as regularly provided by mental health care centers, schools, school collaborations and/or other organizations, except from pharmacological treatment for children's behavioral difficulties and/or behavioral teacher training/support. PAU can also imply that there is no support or treatment.
Study: NCT04732533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation)
Description: Phase 1: The participant will receive 10, 20-minute sessions of tDCS on Monday-Friday, at approximately the same time of day, over two consecutive weeks.~Phase 2: The participant will receive 22, 20-minute sessions of tDCS. 10 sessions will take place over the first two weeks on Monday-Friday, at approximately the same time of day. This will be followed by 3 tDCS sessions per week over four weeks.~Phase 3: The participant will receive up to 260, 20-minute sessions of tDCS. The participant can complete up to 5 tDCS sessions per week over 52 weeks.
Study: NCT05965661

Intervention type: OTHER
Group type: OTHER
Intervention: virtual reality upper limb hand training
Description: The PD patients randomized in the experimental group will receive virtual reality upper limb hand training.

Intervention type: OTHER
Group type: OTHER
Intervention: virtual reality control training
Description: The PD patients randomized in the control group will receive virtual reality control training.
Study: NCT05404308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation with Manipulator in Medical Radiology and a radiotherapist
Description: Weekly consultation with Manipulator in Medical Radiology and a radiotherapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consultation with a radiotherapist
Description: Weekly consultation with a radiotherapist
Study: NCT05266586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg
Description: capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Obicetrapib placebo
Description: tablets; no active ingredient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe placebo
Description: capsules; no active ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ezetimibe placebo
Description: capsules; no active ingredient
Study: NCT05859061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoICE® system (AtriCure, Inc) with CryoSphere (CryoS) probe
Description: Per manufacturer instructions, the cryoprobe will be positioned under direct visualization and ablation of the intercostal nerve will be performed 2-4 cm lateral to the internal mammary artery near the mid-clavicular line. The study team plans to perform each cryoablation (-50°C to -70°C) for 120 seconds to sustain an ablation length of 2-3 cm at each intercostal nerve (bilateral T2 - T6). The probe will be removed after defrosting to avoid mechanical damage to the intercostal nerve. Cryoablation will be performed once hemostasis is achieved and prior to sternal wire placement and chest closure by a provider from the cardiac surgery team.
Study: NCT06073379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Korean manupuncture
Description: Energy assessment on hands and body Correspondence point technique on hands Energy rebalancing with ki Maeks on hands Moxa technique on hands

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo session
Description: Energy assessment on hands and body Correspondence point technique on the hands Energy rebalancing with ki Maeks on hands (use of Qi bong) Moxa technique on hands (placebo moxas)
Study: NCT05137860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.
Study: NCT03953703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: Levocarnitine 1000 mg twice per day for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: Levocarnitine 1000 mg twice per day for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 1000 mg twice per day for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 1000 mg twice per day for 6 weeks
Study: NCT06124053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Voice Therapy
Description: The group voice therapy intervention consists of a total of eight sessions. The session contents include both direct and indirect voice therapy approaches. Each group is composed of three participants. The session durations are planned to be 45-60 minutes each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Voice Therapy
Description: The individual voice therapy intervention consists of a total of eight sessions. The session contents include both direct and indirect voice therapy approaches. The session durations are planned to be 45-60 minutes each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocal Hygiene Education
Description: Regarding vocal hygiene training, information related to voice production and respiratory characteristics will be provided, and guidance on correct and incorrect voice use will be given.
Study: NCT06211335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT04531215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Retrolaminar Block
Description: ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Erector Spinae Plane
Description: ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
Study: NCT06108804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan pain release phenomenon with tapping
Description: Participants in Group A will receive mulligan pain release phenomenon with tapping.First, demographic information will be gathered, pain severity will be measured using NPRS, knee joint range of motion (flexion/extension) will be measured using a goniometer, and functional limitation will be evaluated using a Kujala score.Two sessions of treatment per week with a total of eight session will be given in four weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mulligan pain release phenomenon
Description: Two sessions of treatment per week with a total of eight session will be given in four weeks.Group B will receive mulligan pain release phenomenon only. First, demographic information will be gathered, pain severity will be measured using NPRS. knee joint range of motion (flexion/extension) will be measured using a goniometer, and functional limitation will be evaluated using a Kujala score.
Study: NCT05923957

Intervention type: OTHER
Intervention: TENS and Exercise
Description: High frequency electrical stimulation was done for thirty minutes per day for five days a week for four consecutive weeks. The stimulator provides a biphasic current of 100 Hz frequency. The pulse duration was 200 msec with an (on-off). Stimulus mode (20sec stimulation, 20 sec pause). The maximal stimulation amplitude was 40 - 60 mA
Study: NCT04724226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab; Apatinib
Description: Cryoablation~Drug: Camrelizumab and Apatinib Camrelizumab (200mg), iv, Q3W; Apatinib (250mg), po, QD
Study: NCT04805554

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint Insights decision aid
Description: The Joint Insights decision aid was developed by Dell Medical School faculty in collaboration with OM1, a health outcomes and predictive analytics company. This decision aid uses patient-report outcome measures (PROMs) - specifically, the PROMIS Global and the KOOS JR - along with patient clinical and demographic information (age, sex, race, ethnicity, chronic narcotic use, body mass index), in machine-learning-based predictive analytic models to provide personalized estimates of likely benefit or harm from total knee replacement surgery. The tool is designed to collect PROMs or pull in PROMs collected through other systems (e.g., an EHR or a third-party PROM platform). It also provides condition-specific education to patients with knee OA and allows a patient to reflect on and document their preferences and goals. The personalized risk/benefit report generated by the decision aid is meant to be discussed with the patient's provider to enhance shared decision making.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint Insights decision aid
Description: The Joint Insights decision aid was developed by Dell Medical School faculty in collaboration with OM1, a health outcomes and predictive analytics company. This decision aid uses patient-report outcome measures (PROMs) - specifically, the PROMIS Global and the KOOS JR - along with patient clinical and demographic information (age, sex, race, ethnicity, chronic narcotic use, body mass index), in machine-learning-based predictive analytic models to provide personalized estimates of likely benefit or harm from total knee replacement surgery. The tool is designed to collect PROMs or pull in PROMs collected through other systems (e.g., an EHR or a third-party PROM platform). It also provides condition-specific education to patients with knee OA and allows a patient to reflect on and document their preferences and goals. The personalized risk/benefit report generated by the decision aid is meant to be discussed with the patient's provider to enhance shared decision making.
Study: NCT05052554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-504a
Description: Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-504a
Description: Intravitreal (IVT) injection
Study: NCT05843188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Anti-Inflammatory - antimalarial - aminoquinolines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Antineoplastic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Antineoplastic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Folic acid derivative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Folic acid derivative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Antineoplastic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Antineoplastic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Antineoplastic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Antineoplastic agent
Study: NCT04824521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement
Description: MORE is a mindfulness-based intervention.
Study: NCT04822012

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti COVID19 IgG Antibodies
Description: Detection of antibodies to SARS Cov 19 post infection or vaccination , measurements of female hormones in folicular fluid as compared to serum and Perlecan as a follicular quality marker

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti COVID19 IgG Antibodies
Description: Detection of antibodies to SARS Cov 19 post infection or vaccination , measurements of female hormones in folicular fluid as compared to serum and Perlecan as a follicular quality marker
Study: NCT06200831

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged resection
Description: Patients randomized to staged resection will be operated according to the decision made by the tumor board meeting (liver or colorectal cancer first, based on tumor burden and symptoms), but both resections have to be done within a time period of 4-12 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneous resection
Description: In cases with simultaneous surgery, the liver resection is performed prior to colon resection in order to keep a low central venous pressure during the first part of the surgical procedure and to avoid congestion of the anastomosis line owing to possible Pringle manoeuvre.
Study: NCT04687228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More than Muscles (MTM)
Description: In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Media Advocacy (MA)
Description: MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.
Study: NCT05077865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYMD-1
Description: 150 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYMD-1
Description: 150 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYMD-1
Description: 150 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYMD-1
Description: 150 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching in appearance to MyMD-1 150mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching in appearance to MyMD-1 150mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching in appearance to MyMD-1 150mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching in appearance to MyMD-1 150mg capsule
Study: NCT04674670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine Mesylate Capsules
Description: Healthy controls and fibromyalgia patients will be administered a single dose of bromocriptine (1.25mg, p.o.) to investigate the effect of transiently increasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine Mesylate Capsules
Description: Healthy controls and fibromyalgia patients will be administered a single dose of bromocriptine (1.25mg, p.o.) to investigate the effect of transiently increasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride 400 MG
Description: Healthy controls will be administered a single dose of amisulpride (400mg, p.o.) to investigate the effect of transiently decreasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Healthy controls and fibromyalgia patients will be administered a placebo as for comparison with the effects of bromocriptine (healthy controls and patients) and amisulpride (healthy controls only) on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Healthy controls and fibromyalgia patients will be administered a placebo as for comparison with the effects of bromocriptine (healthy controls and patients) and amisulpride (healthy controls only) on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
Study: NCT05360498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Symptom Management and Survivorship Handbook (SMSH) and Telephone Interpersonal Counseling (TIP-C)
Description: This group will get weekly calls for 16 weeks and two follow-up assessments. Participants will be asked to rate their symptoms on a 0-10 scale at each call. This group will receive the SMSH, a printed evidence-based self-care management handbook with specific modules, that will be directed to use for symptoms rated 4 or higher on a 0-10 scale. For symptoms ≥7, participants will be asked to report the symptom to their provider. At each weekly call, participants will be asked: if they tried symptom self-management strategies and, if yes, which strategies were used. These calls will take 10-15 minutes. If during 8 weeks of SMSH, either the survivor or caregiver have distress (symptoms 4 or greater on a 0-10 scale) for any two consecutive weeks during weeks 2-8, TIP-C will be added for the dyad for 8 weeks. The addition of TIP-C can start between weeks 4 and 9. Dyads will continue the SMSH in addition to the TIPC. TIP-C calls will take 35-45 minutes.
Study: NCT05660577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens
Description: new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens
Study: NCT03963817

Intervention type: DIAGNOSTIC_TEST
Intervention: adaptive optics AO-OCT/AF instrument
Description: Using the new adaptive optics AO-OCT/AF instrument, the study team will image 10 normal subjects in order to optimize image acquisition and interpretation.

Intervention type: DIAGNOSTIC_TEST
Intervention: adaptive optics AO-OCT/AF instrument
Description: Using the new adaptive optics AO-OCT/AF instrument, the study team will image 40 adult subjects with age-related macular degeneration (AMD) who have non-neovascular AMD and soft drusen or subretinal drusenoid deposits in the macula.
Study: NCT04575948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moringa Oleifera
Description: Non toxic Moringa extract with antibacterial and antiplaque effect will be used

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Commercial 0.12% chlorhexidine digluconate mouthwash twice daily (each morning and before bedtime during the 21-day study period) after intake of food. The patient will be asked to use 15 ml of mouthwash swish it for 60 sec. then expectorate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Base formula
Description: Base formula is a negative control
Study: NCT05360498

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI Brochure
Description: The attention control arm will receive an NCI brochure: Facing Forward: Life After Cancer Treatment. This group will also get weekly calls for 16 weeks and complete two exit interviews. The NCI brochure will not be address, the purpose of these calls will only be to record participant's symptoms throughout the study. These calls will take about 10 minutes or less.